

# Financial Tear Sheet

## Corporate Profile

Altimmune is a clinical stage immunotherapeutic biotechnology company located in Montgomery County, MD with additional operating sites in London, UK and Strasbourg, France. By leveraging the complementary attributes of its two innovative vaccine delivery platforms, RespirVec™ and Densigen™, Altimmune is able to design and develop immunotherapeutic products tailored to address a wide range of disease indications including acute respiratory infections, chronic viral infections and cancer, with the potential for fundamental advantages over competing products.

## Corporate Profile


### ALT (COMMON STOCK)

**\$2.66**

Change (%) ▲ 0.16 (6.40%)

Volume 188,257

Data as of 10/19/17 4:00 p.m. ET  
 Data provided by Nasdaq. Minimum 15 minutes delay  
[Refresh quote](#)



## Recent Press Releases

September 20, 2017

[ALTIMMUNE ANNOUNCES ITS PHASE 2 FLU VACCINE TRIAL WITH NASOVAX OPEN FOR ENROLLMENT](#)

September 19, 2017

[ALTIMMUNE TO PROVIDE CORPORATE UPDATE AT THE LADENBURG THALMANN 3RD ANNUAL HEALTHCARE CONFERENCE](#)

September 06, 2017

[ALTIMMUNE TO PROVIDE CORPORATE UPDATE AT THE RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE](#)

## Upcoming Events



September 26, 2017 12:00 p.m. ET

[ALTIMMUNE, INC. AT LADENBURG THALMANN 2017 HEALTHCARE CONFERENCE](#)



September 12, 2017 10:25 a.m. ET

[ALTIMMUNE, INC. AT RODMAN & RENSHAW 19TH ANNUAL GLOBAL INVESTMENT CONFERENCE](#)



August 10, 2017 8:30 a.m. ET

[SECOND QUARTER 2017 EARNINGS CONFERENCE CALL](#)

## Sec Filings

Filing Date	Form	Description	Filing Group
10/19/17	SC 13D/A	An amendment to a SC 13D filing	Other
10/18/17	8-K	Report of unscheduled material events or corporate event	Current Reports
10/18/17	10-Q/A	Amendment to a previously filed 10-Q	Quarterly Filings

10/17/17	4	Statement of changes in beneficial ownership of securities	3,4,5
10/17/17	4	Statement of changes in beneficial ownership of securities	3,4,5
10/17/17	4	Statement of changes in beneficial ownership of securities	3,4,5
10/17/17	4	Statement of changes in beneficial ownership of securities	3,4,5
10/17/17	4	Statement of changes in beneficial ownership of securities	3,4,5
10/17/17	4	Statement of changes in beneficial ownership of securities	3,4,5
09/28/17	8-K	Report of unscheduled material events or corporate event	Current Reports

## Primary IR Contact

Ashley Robinson  
LifeSci Advisors, LLC  
Phone: (617) 775-5956  
E-mail: [arr@lifesciadvisors.com](mailto:arr@lifesciadvisors.com)